CLDI (Calidi Biotherapeutics) Shares Buyback Ratio %: -344.96 (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Calidi Biotherapeutics Shares Buyback Ratio %?

Calidi Biotherapeutics CLDI -4.76% Shares Buyback Ratio % is -344.96 as of Jul. 26, 2026. The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Calidi Biotherapeutics's current shares buyback ratio was -344.96%.

Calidi Biotherapeutics Shares Buyback Ratio % Related Terms

Calidi Biotherapeutics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Shares Buyback Ratio % Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial 0.00 0.00 1.00 -484.46 -317.17

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -53.12 -8.61 -140.04 -4.50 -63.32

Calidi Biotherapeutics Shares Buyback Ratio % Calculation

Calidi Biotherapeutics's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(1.730 - 7.217) / 1.730
=-317.17%

Calidi Biotherapeutics's Shares Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2025 ) - Shares Outstanding (EOP) (A: Mar. 2026 )) / Shares Outstanding (EOP) (A: Dec. 2025 )
=(7.217 - 11.787) / 7.217
=-63.32%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -344.96 mean?
Calidi Biotherapeutics (CLDI) has a Shares Buyback Ratio % of -344.96 as of Jul. 26, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Shares Buyback Ratio % too high?
Calidi Biotherapeutics' current Shares Buyback Ratio % is -344.96.
How does Calidi Biotherapeutics' Shares Buyback Ratio % compare to DCOY and CDT?
Calidi Biotherapeutics' Shares Buyback Ratio % of -344.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Shares Buyback Ratio % is -344.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Shares Buyback Ratio % of -344.96. The current Shares Buyback Ratio % is -344.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Shares Buyback Ratio % is -344.96 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.